Incyte has announced a strategic partnership to embed Edison Scientific’s AI platform, Kosmos, across its drug discovery and clinical development workflows. Under the agreement, Kosmos will ingest Incyte's translational and human clinical trial data to generate highly predictive models of therapeutic performance.
Developed by San Francisco based Edison Scientific, a late 2025 spinout from the nonprofit research organization Future House, Kosmos is designed as an agentic AI scientist. Unlike traditional static software that merely processes data, Kosmos actively learns from its environment. Incyte will leverage its own proprietary data to train the platform, establishing an active feedback loop where the AI’s predictive accuracy continuously evolves.
The deployment will initially target high impact bottlenecks in Incyte's early research pipelines before potentially expanding across the global R&D organization. Dr. Pablo Cagnoni, Incyte’s Global Head of R&D, emphasized that the collaboration shifts AI from a passive analytical tool to a learning partner, ultimately aimed at accelerating target validation and improving clinical success rates.